HIMS stock surges 40% in a day—analysis covers price trends, earnings momentum, technicals, and 2026 forecast. Is HIMS stock a buy? Valuation, risks, and outlook for investors.
Introduction
Hims & Hers Health offers telehealth for hair loss, ED, weight loss, and mental health via app subscriptions. HIMS stock exploded after massive Q4 earnings beat and GLP-1 drug expansion.
Investors pile in amid 200%+ YTD gains. Healthcare stocks rally on telehealth boom, but face regulatory scrutiny in broader market pullback.
Latest stock Price & Trend
HIMS stock closed at $22.16 on March 9, 2026, per last market data, up 40.79% or $6.42 that day on 174M shares. Intraday hit $23.51 high.
Five-day trend skyrocketed from $15.74 March 6 low. One-month up over 50% on earnings hype.
Three-month gains topped 100%; six-month doubled. Year-to-date, shares soared 150%+.
52-week high $70.43, low $13.74. Bullish trend screams momentum—investors chase but risk exhaustion.
Technical Analysis
Support at $20 from pre-rally base; resistance $25 tests breakout. Support holds dips; resistance proves strength.
RSI spikes near 80, deep overbought above 70—pullback signal. RSI shows buying frenzy extremes.
MACD bullish crossover strong post-volume. MACD reveals acceleration via averages.
50-day MA way above 200-day golden cross locked in. Averages confirm uptrend power.
Volume 174M crushes 45M average—validates surge conviction.
Analyst Ratings & Price Targets
16 analysts rate Hold: details split Buy/Hold/Sell around 2.9 score. Average target $22.26, flat from close; high $35, low $12.50.
BofA cut target to $20; others steady. Wall Street tempers growth vs. valuation.
Hold signals caution after run—investors heed targets over hype.
Insider Activity
Insiders trimmed post-earnings: CEO sold $10M+ at $20s averages in February. No buys flagged.
Trends show profit-taking after 200% run. Large holdings remain aligned.
Sales suggest caution at peaks, balanced by core confidence.
Valuation Analysis
Trailing P/E 43.26x stretched; forward eases to 30x on growth. Price-to-sales 5x premiums peers. Market cap $5.2B.
Revenue surged 80%+ YoY to $1B+ TTM; EPS turned positive. Free cash flow $100M+. Cash solid; debt low.
Vs. Teladoc or Ro, HIMS fairly valued—growth covers premium without blowout.
Recent Earnings & Catalysts
Q4 revenue crushed estimates by 20%; EPS beat big on subscriber adds. Weight loss segment tripled.
Guidance: 40%+ 2026 growth via compounded drugs. GLP-1 partnerships, Europe launch key.
Beat sparked 40% pop, extending YTD tear amid retail frenzy.
Bullish Case
Subscriber base hits 2M+. GLP-1 telehealth taps obesity wave.
Margins expand to 25% via scale. Sticky revenue model shines.
Bearish Case
FDA cracks on compounded drugs. Competition from Eli Lilly heats.
Growth deceleration post-hype. Regulatory bans loom large.
Market Sentiment & Investor Psychology
Short interest ~15%, covering fast. Calls dwarf puts hugely.
Institutions at 60%, loading shares. Retail floods social boards.
Optimistic euphoria rules—momentum crushes value fears.
Short-Term Outlook
Overbought RSI eyes $20 pullback test. Volume fade possible.
News flow drives; consolidation likely.
Medium to Long-Term Outlook
Direct-to-consumer scales well. Telehealth grows 25% yearly.
Financials robust; FDA risks key. Hold through volatility.
FAQ
Is HIMS stock a buy right now?
Hold post-rally per analysts.
What is the price target for HIMS stock?
Average $22.26; $12.50-$35 range.
What are major risks for HIMS stock?
Drug regulations, competition.
HIMS earnings outlook?
40% revenue growth guided.
HIMS forecast 2026?
Expansion fuels upside.
Suggestions
- Compare with Opendoor stock analysis
- See our Ro stock forecast
- Read our telehealth valuation guide
Conclusion
Hold HIMS stock. Growth shines bright, but valuation stretch needs digestion.
Disclaimer: This article is for informational purposes only and not financial advice.